| 摘要 |
This disclosure relates to stable pharmaceutical formulations of the drug fosinopril sodium comprising a lubricant which is sodium stearate or a mixture composed of stearic acid esters, propylene glycol monoesters, distilled monoglycerides, sodium stearoyl lactylate, and silicon dioxide.
|
